ALR Technologies Launches GluCurve Pet CGM in Canada
ALRTF has more than doubled off its 52-week low of $0.001.
Summary
ALR Technologies announced the launch of its GluCurve Pet CGM in Canada, expanding its market reach and offering a new potential revenue source for the micro-cap company.
Key Events · Product Development and Regulatory · ALRTF
-
GluCurve Pet CGM Launched in Canada
ALR Technologies has commenced sales of its GluCurve Pet Continuous Glucose Monitor (CGM) in Canada, with initial shipments arriving at the Canadian distribution center.
-
Market Expansion for Key Product
This launch marks a significant market expansion for GluCurve, the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs.
-
Addresses Going Concern Context
The new revenue opportunity comes after the company's 20-F filing on April 30, 2026, which disclosed substantial doubt about its ability to continue as a going concern, making new sales channels critical.
Analysis · ALRTF · Industrial Applications And Services
ALR Technologies has launched its GluCurve Pet Continuous Glucose Monitor (CGM) in Canada. This market expansion is an important development, especially following the company's recent 20-F filing which raised substantial doubt about its ability to continue as a going concern. New product revenue streams are critical for the company's financial viability.
At the time of this filing, ALRTF was trading at $0.01 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $0.00 to $0.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.